Anhydrous Amiloride Hydrochloride for Bipolarity
This study is active but not recruiting in France. It is testing anhydrous Amiloride Hydrochloride for Bipolarity.
Key information made simple
What is this study testing?
This study is testing whether Anhydrous Amiloride Hydrochloride may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may receive Anhydrous Amiloride Hydrochloride, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in France.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including Néphrologie, Hôpital Henri-Mondor in Créteil and Physiologie Explorations fonctionnelles multidisciplinaires, Hôpital Bichat in Paris. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually meeting the main study requirements, while common reasons not to take part include pregnancy or breastfeeding and other factors that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Recruitment status
- Active Not Recruiting
- Estimated enrollment
- Not clearly listed
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- France
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05044611
- Official title
- AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial
- Official source
- Official registry link
Want help reviewing this study?
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in France.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Anhydrous Amiloride Hydrochloride, Placebo. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with bipolarity; age range: From 18 Years to 70 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Assistance Publique - Hôpitaux de Paris, which appears to be unknown or unclear. The listed contact or investigator is Assistance Publique - Hôpitaux de Paris, affiliated with Assistance Publique - Hôpitaux de Paris. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that the study is active but not currently recruiting. This usually means participants may already be involved, but new participants may not be accepted.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me
